{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T20:14:25Z","timestamp":1773519265916,"version":"3.50.1"},"reference-count":18,"publisher":"Pensoft Publishers","issue":"6","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FM"],"abstract":"<jats:p><jats:bold>Introduction<\/jats:bold>: The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize <jats:sup>131<\/jats:sup>I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT\/CT studies have been utilized to increase the diagnostic sensitivity and specificity.<\/jats:p>\n          <jats:p><jats:bold>Aim<\/jats:bold>: To evaluate the clinical role of post-treatment <jats:sup>131<\/jats:sup>I SPECT\/CT imaging in the management of DTC.<\/jats:p>\n          <jats:p><jats:bold>Materials and methods<\/jats:bold>: The study included 564 patients (384 women and 180 men) aged 12 to 83 years with DTC referred to our hospital between 2011 and 2021. A post therapeutic <jats:sup>131<\/jats:sup>I whole-body scintigraphy (WBS) with SPECT\/CT imaging was performed.<\/jats:p>\n          <jats:p><jats:bold>Results<\/jats:bold>: 370 (65%) cases with papillary carcinoma, 101 (18%) cases with follicular carcinoma, and 93 (17%) cases with follicular variant of papillary DTC were histologically proven. <jats:sup>131<\/jats:sup>I WBS was positive in 423 (75%) cases. SPECT\/CT showed thyroid remnant in 237 (42%) patients, tumor persistence \u2013 in 15 (2.7%), and local recurrence in the thyroid bad in 17 (3%) cases. Enlarged cervical and mediastinal lymph nodes were visualized in 141 (25%) cases. Forty-eight (8.5%) patients had pulmonary metastases, 14 had osteolytic bone lesions and 6 (1.4%) had brain metastases detected on the SPECT\/CT images. Negative <jats:sup>131<\/jats:sup>I SPECT\/CT data influenced significantly the clinical management of a large cohort with recurrent and metastatic DTC, leading to rejection of radioiodine treatment as a therapeutic alternative.<\/jats:p>\n          <jats:p><jats:bold>Conclusion<\/jats:bold>: SPECT\/CT improved the <jats:sup>131<\/jats:sup>I WBS accuracy, thus changing the management of DTC determining indications for surgery, the need to give or withhold <jats:sup>131<\/jats:sup>I therapy, and selecting cases for radiotherapy or chemotherapy in order to personalize the treatment.<\/jats:p>","DOI":"10.3897\/folmed.66.e139177","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T15:24:54Z","timestamp":1735831494000},"page":"776-786","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective study of post-treatment 131I SPECT\/CT imaging for personalizing therapy of patients with differentiated thyroid cancer"],"prefix":"10.3897","volume":"66","author":[{"given":"Sonya","family":"Sergieva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8838-9975","authenticated-orcid":true,"given":"Teodor","family":"Sofiyanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozhil","family":"Robev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-9370","authenticated-orcid":true,"given":"Milena","family":"Dimcheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albena","family":"Fakirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2258","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"139177_B1","doi-asserted-by":"crossref","unstructured":"Spanu A, Solinas ME, Chessa F, et al. 131I SPECT\/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med 2009; 50(2):184\u201390.","DOI":"10.2967\/jnumed.108.056572"},{"key":"139177_B2","unstructured":"Avram AM, Giovanella L, Greenspan B, et al. SNMMI Procedure Standard\/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J Nucl Med 2022; 63(6):15N\u201335N."},{"key":"139177_B3","unstructured":"P\u00e9rault C, Schvartz C, Wampach H, et al. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne. J Nucl Med 1997; 38:(8):1234\u201342."},{"key":"139177_B4","doi-asserted-by":"crossref","unstructured":"Al Hatmi A, Jain A, Mittal AK, et al. Evaluation of diagnostic value of SPECT\/CT imaging in post-radioiodine therapy in thyroid cancer. SQU Medical Journal (Clinical and Basic Research) 2022; 22(1);74\u201381.","DOI":"10.18295\/squmj.4.2021.054"},{"key":"139177_B5","doi-asserted-by":"crossref","unstructured":"Van den Wyngaert T, Elvas F, Schepper SD, et al. SPECT\/CT: standing on the shoulders of giants, it is time to reach for the sky! J Nucl Med 2020; 61(9):1284\u201391.","DOI":"10.2967\/jnumed.119.236943"},{"key":"139177_B6","doi-asserted-by":"crossref","unstructured":"Israel O, Pellet O, Biassoni L, et al. Two decades of SPECT\/CT \u2013 the coming of age of a technology: an updated review of literature evidence. Eur J Nucl Med Mol Imaging 2019; 46(10):1990\u20132012.","DOI":"10.1007\/s00259-019-04404-6"},{"key":"139177_B7","doi-asserted-by":"crossref","unstructured":"Hertz B. A tribute to dr. Saul Hertz: The discovery of the medical uses of radioiodine. J Nucl Med 2019; 18:8\u201312.","DOI":"10.4103\/wjnm.WJNM_107_18"},{"key":"139177_B8","doi-asserted-by":"crossref","unstructured":"Michael R, Tuttle RM, Ahuja S, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer. J Thyroid 2019; 29(4):461\u201370.","DOI":"10.1089\/thy.2018.0597"},{"key":"139177_B9","doi-asserted-by":"crossref","unstructured":"Sergieva S, Mihaylova I, Alexandrova E, et al. SPECT-CT in radiotherapy planning, with main reference to patients with breast cancer. Current Radiopharmaceuticals 2015; 8:9\u201318.","DOI":"10.2174\/1874471008666150316221722"},{"key":"139177_B10","doi-asserted-by":"crossref","unstructured":"Mariani G, Bruselli L, Kuwert T, et al. A review on the clinical uses of SPECT\/CT. EAMMI 2010; 37(10):1959\u201385.","DOI":"10.1007\/s00259-010-1390-8"},{"key":"139177_B11","doi-asserted-by":"crossref","unstructured":"Qichang W, Lin B, Gege Z, et al. Diagnostic performance of F-18 FDG PET\/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol 2019; 181:93\u2013102.","DOI":"10.1530\/EJE-19-0261"},{"key":"139177_B12","doi-asserted-by":"crossref","unstructured":"Dong MJ, Liu ZF, Zhao K, et al. Value of 18-F FDG PET\/CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 2009; 30:639\u201350.","DOI":"10.1097\/MNM.0b013e32832dcfa7"},{"key":"139177_B13","doi-asserted-by":"crossref","unstructured":"Feine U, Lietzenmayer R, Hanke JP, et al. 18-F FDG whole body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18-FDG and I-131. Nuklearmedizin 1995; 34(4):127\u201334.","DOI":"10.1055\/s-0038-1629813"},{"key":"139177_B14","doi-asserted-by":"crossref","unstructured":"Choudhury PS, Gupta M. Theranostics and precision medicine special feature: review article. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol 2018; 9(2):80\u2013136.","DOI":"10.1259\/bjr.20180136"},{"key":"139177_B15","doi-asserted-by":"crossref","unstructured":"Zampella E, Michelle K, Pace L, et al. PET\/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging 2021; 102:515\u201323.","DOI":"10.1016\/j.diii.2021.04.004"},{"key":"139177_B16","doi-asserted-by":"crossref","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26(1):1\u201333.","DOI":"10.1089\/thy.2015.0020"},{"key":"139177_B17","doi-asserted-by":"crossref","unstructured":"Filetti S, Durante C, Hartl D, et al. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annal Oncol 2019; 30:1856\u201383.","DOI":"10.1093\/annonc\/mdz400"},{"key":"139177_B18","unstructured":"Haddad R, Bischoff L, Ball D, et al. NCCN guidelines thyroid carcinoma \u2013 follicular carcinoma, version 1. J Natl Compr Canc Netw 2022."}],"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"https:\/\/foliamedica.bg\/article\/139177\/download\/pdf\/","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article\/139177\/download\/xml\/","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article_preview.php?id=139177&skip_redirect=1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T15:25:02Z","timestamp":1735831502000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliamedica.bg\/article\/139177\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,31]]}},"URL":"https:\/\/doi.org\/10.3897\/folmed.66.e139177","relation":{},"ISSN":["1314-2143","0204-8043"],"issn-type":[{"value":"1314-2143","type":"electronic"},{"value":"0204-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}